At PolTREG, we are very excited to announce we have received a patent in the US protecting an important part of our business: the manufacturing of T-regulatory cells (T-regs) to treat Type-1 Diabetes (T1D), and ways the therapy is administered.  “The decision by the US Patent and Trademark Office (USPTO) complements our large intellectual property … Continued

PolTREG has identified a promising efficacy biomarker that may facilitate monitoring the health of Type-1 diabetes patients treated with T-regulatory cells. This is described in a study, published in the prestigious magazine International Immunopharmacology. “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies,” Chief Executive Officer Piotr Trzonkowski said in … Continued

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellular therapies(or Advanced Therapy Medicinal Products) from the Chief Pharmaceutical Inspectorate in Poland. We can now seek permission to perform clinical trials at the site, including for diseases such as Type-1 Diabetes (T1D) and Multiple Sclerosis with our lead asset PTG-007. PolTREG has more than 17 … Continued

PolTREG S.A., a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of Chief Business Development Officer as of today, to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise … Continued

Major global investors continued to accumulate PolTREG shares in 2023, adding another 129,000 shares, and bringing the total to 1.27 million. Investment funds including well-known investors like TFI Allianz Polska – part of the Allianz Group – and Norges Bank Investment Management, collectively hold over 25% of PolTREG’s shares. The trust of these global investors underscores the significant commercial potential … Continued

Science has gained deep understanding of T-regulatory (Treg) cells and how to use them for therapeutical purposes in auto-immune diseases. This is what three leading research institutes in Europe showed in a peer-reviewed article in Frontiers in Immunology, the world’s fifth-most cited immunology journal. Contributors were PolTREG S.A. CEO Prof. Piotr Trzonkowski, and researchers from … Continued

PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The decision paves “the way for rapid, unimpeded commercialization of PolTREG’s cell therapies,” CEO Prof. Piotr Trzonkowski was quoted as saying in today’s press … Continued

There was ample interest for PolTREG’s unrivalled expertise in cell therapy for autoimmunedisease at the Biotech Showcase event in San Francisco last week. Piotr Trzonkowski and Mariusz Jablonski met with investors and sell-side analysts, almost 20meetings spread out over three days. PolTREG has all the promises of Treg autoimmune therapyin one hand, offering hope for patients with diseases such … Continued

We are excited to announce that PolTREG will be attending the Biotech Showcase during J.P. Morgan Healthcare Week 2024 in San Francisco, from January 8 to 11. Meet CEO Prof. Piotr Trzonkowski and Chief Business Officer Mariusz Jabłoński to discuss PolTREG’s cutting-edge technology in Treg cell therapies as a promising new form of personalized treatment … Continued

PolTREG has just completed construction of the second phase of one of Europe’s most advanced cell and gene therapy manufacturing facilities, featuring: – 15 stand-alone production lines – annual capacity of 750 batches (of two Treg cell treatments each) – 4000 sq. m of space “The strategic value of our facility is high for several … Continued